MX2018006006A - Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation. - Google Patents

Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation.

Info

Publication number
MX2018006006A
MX2018006006A MX2018006006A MX2018006006A MX2018006006A MX 2018006006 A MX2018006006 A MX 2018006006A MX 2018006006 A MX2018006006 A MX 2018006006A MX 2018006006 A MX2018006006 A MX 2018006006A MX 2018006006 A MX2018006006 A MX 2018006006A
Authority
MX
Mexico
Prior art keywords
teneligliptin
solvates
intermediates
preparation
oxalate
Prior art date
Application number
MX2018006006A
Other languages
Spanish (es)
Inventor
Mahadev Kadam Suresh
Parsottam Kansagra Bipin
Bhaskar Bhirud Shekhar
Kantilal Kale Shrikrishna
Kumar Dwivedi Rajesh
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63039388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2018006006A publication Critical patent/MX2018006006A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

The present invention provides oxalate salts of teneligliptin and solvates thereof exhibiting superior physiochemical properties. In particular, crystalline form of teneligliptin 2.5 oxalate 1.0 hydrate and crystalline form of teneligliptin 3.0 oxalate 1.0 hydrate are disclosed. Also provided are methods of preparing the same, and uses thereof.
MX2018006006A 2017-02-03 2018-02-02 Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation. MX2018006006A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721004095 2017-02-03
PCT/IB2018/050652 WO2018142327A1 (en) 2017-02-03 2018-02-02 Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation

Publications (1)

Publication Number Publication Date
MX2018006006A true MX2018006006A (en) 2019-05-16

Family

ID=63039388

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006006A MX2018006006A (en) 2017-02-03 2018-02-02 Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation.
MX2018006005A MX2018006005A (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of teneligliptin and solvates thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006005A MX2018006005A (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of teneligliptin and solvates thereof.

Country Status (10)

Country Link
JP (2) JP2019512460A (en)
KR (2) KR20180099635A (en)
CN (2) CN108697707A (en)
AU (2) AU2018202960A1 (en)
BR (2) BR112018010748A2 (en)
EA (1) EA039402B1 (en)
MX (2) MX2018006006A (en)
RU (2) RU2018120216A (en)
TW (2) TW201831473A (en)
WO (2) WO2018142327A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209350A1 (en) * 2019-04-12 2020-10-15 田辺三菱製薬株式会社 Rapid disintegrating oral tablet for treatment of diabetes
CN110028496A (en) * 2019-04-26 2019-07-19 梯尔希（南京）药物研发有限公司 A kind of synthetic method of teneligliptin related impurities
WO2021053564A1 (en) * 2019-09-17 2021-03-25 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
KR20210121421A (en) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 Method for preparing amorphous teneligliptin 2.5hydrobromide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319322B (en) * 2003-11-13 2010-01-11 Ono Pharmaceutical Co Frozen-dried preperation containing prostaglandin
BRPI0607863B8 (en) * 2005-02-18 2021-05-25 Mitsubishi Pharma Corp 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl crystalline salt }thiazolidine and its preparation process
EA029759B1 (en) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents
EP3646859A1 (en) * 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
BR112015004029B1 (en) * 2012-08-31 2022-03-29 Glenmark Pharmaceuticals Limited Process for preparing teneligliptin, a compound or a salt or hydrate thereof
JP6088872B2 (en) * 2013-03-22 2017-03-01 サラヤ株式会社 Sophorolipid powder with suppressed decomposition of lactone type sophorolipid
JP5922310B2 (en) * 2013-07-25 2016-05-24 株式会社三和化学研究所 Pharmaceutical formulation
WO2015019238A1 (en) * 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
CN104650065A (en) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 Teneligliptin compound
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions
WO2015173779A1 (en) * 2014-05-16 2015-11-19 Micro Labs Limited Process for the preparation of teneligliptin and its novel intermediates
CN105294673B (en) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 A kind of hydrobromic acid replaces the synthetic method of Ge Lieting
EP3201191A1 (en) * 2014-10-01 2017-08-09 Mylan Laboratories Ltd. Complex of amorphous empagliflozin and a cyclodextrin
WO2016104643A1 (en) * 2014-12-25 2016-06-30 田辺三菱製薬株式会社 Solid preparation for treating diabetes

Also Published As

Publication number Publication date
CN108697707A (en) 2018-10-23
BR112018010748A2 (en) 2018-12-04
TW201831473A (en) 2018-09-01
TW201834655A (en) 2018-10-01
JP2019512460A (en) 2019-05-16
AU2018202623A1 (en) 2018-08-23
EA039402B1 (en) 2022-01-24
RU2018120216A (en) 2021-05-07
CN108884089A (en) 2018-11-23
MX2018006005A (en) 2019-05-16
AU2018202960A1 (en) 2018-08-23
BR112018010759A2 (en) 2018-12-04
EA201992376A1 (en) 2020-03-23
RU2742418C1 (en) 2021-02-05
KR20180100554A (en) 2018-09-11
JP2019508385A (en) 2019-03-28
KR20180099635A (en) 2018-09-05
WO2018142327A1 (en) 2018-08-09
WO2018142334A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2018006006A (en) Oxalate salts of teneligliptin and solvates thereof, intermediates, process of preparation.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2022007912A (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-iso propyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde.
MX2021015102A (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MX2022015106A (en) Process for preparing tapinarof.
WO2018029711A3 (en) Process for the preparation of venetoclax
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
WO2016207914A3 (en) Methods for preparing oltipraz
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
WO2015121379A3 (en) Process for producing vanillin
MX2019002346A (en) Compositions comprising rebaudioside j.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MY184366A (en) Pyrazines modulators of gpr6
WO2015111085A3 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
WO2018125880A8 (en) Nrf2 activator
MX2021007141A (en) Substituted heterocycle fused gamma-carbolines synthesis.
SG11201913520YA (en) Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
MY188420A (en) Crystalline forms of (s)-afoxolaner
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
GEP20207127B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
MX2021007143A (en) Substituted heterocycle fused gamma-carbolines synthesis.